Adult Influenza Vaccination Text Message Reminders

Influenza Vaccination Clinical Trial

Official title:

Adult Influenza Vaccination Text Message Reminders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01942824
• Other study ID #: AAAK5058_2
• Status: Completed
• Phase: N/A
• First received: September 8, 2013
• Last updated: June 22, 2014
• Start date: September 2013
• Est. completion date: May 2014

Study information

• Verified date: June 2014
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Influenza infection leads to on average 24,0000 deaths and 150,000 hospitalizations annually. While vaccination is the cornerstone of preventing influenza infection, vaccination coverage in adults is low with only 35% vaccinated by end of November. Latino adults have the lowest coverage rates. Text message reminders have been used successfully for improving influenza vaccination for children. This study will assess the use of text messaging to improve influenza vaccination coverage rates in a largely minority, publicly insured adult population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7250
• Est. completion date: May 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• > or = 18 years of age,

• at least one visit to the AIM clinic during the previous year

• a cell phone number in the registration system

• fluent in English or Spanish. Exclusion criteria

Exclusion Criteria:

• Receipt of influenza vaccination during the 2013-2014 influenza season prior to randomization.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Influenza Vaccination
• Influenza, Human

Intervention

Behavioral:
• Text Messages

Locations

Country	Name	City	State
United States	Columbia University	NY	New York

Sponsors (1)

Lead Sponsor	Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Timeliness of vaccination	Days from start of intervention to vaccination	6 months	No
Secondary	Receipt of influenza vaccine dose	Proportion of individuals in each group receiving an influenza dose by December 31, 2013	15 weeks	No
Secondary	Receipt of Influenza vaccine dose, end of season	Proportion of individuals in each group receiving an influenza dose by March 31st, 2014	28 weeks	No